Hepatitis C: Clinical Trials

42 trials for Hepatitis C, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

42 terminated. 42 Phase 2, 9 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 242Terminated 42
Phase 19Terminated 9
Phase 34Terminated 4

Follow Hepatitis C: new trials by email Literature Review of Hepatitis C trials Research Report on Hepatitis C

Trials (filtered) newest first · largest first

All 42 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Ambrisentan - Cirrhosis, Portal Hypertension
Phase 2TerminatedNoorik Biopharmaceuticals AG192019-04-112021-02-26
Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection
SOF/VEL/VOX - Hepatitis C Virus Infection
Phase 2TerminatedGilead Sciences212019-01-282020-10-23
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
Daclatasvir, Sofosbuvir - Hepatitis C, Chronic Hepatitis
Phase 2TerminatedBristol-Myers Squibb52018-06-252021-04-20
Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C
20mg ezetimibe, Placebo, 40mg ezetimibe - Chronic Hepatitis C
Phase 2TerminatedVA Office of Research and Development22018-04-162022-06-06
Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
Uprifosbuvir, Ruzasvir, Ribavirin - Hepatitis C
Phase 2TerminatedMerck Sharp & Dohme LLC2822016-11-162021-02-02
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
Uprifosbuvir 450 mg, Ruzasvir 60 mg - Hepatitis C, Chronic
Phase 2TerminatedMerck Sharp & Dohme LLC1602016-05-032019-06-26
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Ledipasvir/sofosbuvir, Ribavirin - HIV-1 Infection, Hepatitis C
Phase 2TerminatedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections72016-02-172018-05-02
Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
MK-3682B, Ribavirin - Hepatitis, Hepatitis C
Phase 2TerminatedMerck Sharp & Dohme LLC942015-12-102024-05-22
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV) - HIV Infections, Hepatitis C
Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)462015-09-162021-11-04
Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies
JKB-122 5mg, JKB-122 15mg, JKB-122 35mg - Chronic Hepatitis C
Phase 2TerminatedTaiwanJ Pharmaceuticals Co., Ltd542014-05-012020-07-21
A Health Intervention to Prevent Depression Hepatitis C Patients
Exercise, Health Education - Hepatitis C, Major Depressive Disorder
Phase 2 / Phase 3TerminatedUniversity of Texas Southwestern Medical Center12013-06-012016-12-29
Interaction Between Paroxetine and Telaprevir
Paroxetine, telaprevir - Hepatitis C Infection, Depression
Phase 2TerminatedRadboud University Medical Center32013-05-012020-12-08
Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C
Ribavirin, Hydroxychloroquine - Hepatitis C
Phase 1 / Phase 2TerminatedBioLineRx, Ltd.42013-04-012014-08-28
Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C
Eltrombopag - Thrombocytopenia, Hepatitis C
Phase 2 / Phase 3TerminatedUniversity of Texas Southwestern Medical Center72013-04-012019-11-13
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
Telaprevir, Peginterferon alfa-2b, Ribavirin - Hepatitis C
Phase 1 / Phase 2TerminatedVertex Pharmaceuticals Incorporated422013-01-012016-07-20
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C
MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2) - Hepatitis C Infection
Phase 2TerminatedMassBiologics112012-11-212021-02-05
Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients
implantation - Hepatitis C
Phase 1 / Phase 2TerminatedMedgenics Medical Israel Ltd.32012-10-012016-09-13
Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a - Hepatitis C
Phase 2TerminatedBristol-Myers Squibb2102012-05-012015-11-04
An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a - Hepatitis C
Phase 2TerminatedVertex Pharmaceuticals Incorporated612012-02-012015-06-18
Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)
Grazoprevir, Placebo to Grazoprevir, Peginterferon alfa-2b (Peg-IFN) - Hepatitis C, Chronic
Phase 2TerminatedMerck Sharp & Dohme LLC52011-11-282024-05-22

Showing 20 of 42. Sign in to see all of them.

Narrower conditions

Hepatitis C, Chronic (13)  ·  Hepatitis (5)  ·  Liver Diseases (3)  ·  Depression (2)  ·  HIV Infections (2)  ·  Hepatitis B (2)  ·  Hepatitis, Chronic (2)  ·  Thrombocytopenia (2)  ·  Virus Diseases (2)  ·  Ascites (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Carcinoma (1)  ·  Carcinoma, Hepatocellular (1)  ·  Depressive Disorder, Major (1)

Broader conditions

Blood-Borne Infections (42)  ·  Communicable Diseases (42)  ·  Infections (42)  ·  Digestive System Diseases (41)  ·  Flaviviridae Infections (41)  ·  Hepatitis, Viral, Human (41)  ·  RNA Virus Infections (41)  ·  Virus Diseases (40)  ·  Liver Diseases (39)  ·  Hepatitis (37)  ·  Pathologic Processes (17)  ·  Pathological Conditions, Signs and Symptoms (17)  ·  Disease Attributes (16)  ·  Chronic Disease (15)  ·  Hepatitis, Chronic (13)

Interventions

Ribavirin (13)  ·  peginterferon alfa-2a (4)  ·  peginterferon alfa-2b (4)  ·  telaprevir (4)  ·  Sofosbuvir (2)  ·  daclatasvir (2)  ·  ruzasvir (2)  ·  uprifosbuvir (2)  ·  BMS-986094 (1)  ·  Blood Specimen Collection (1)  ·  Colchicine (1)  ·  Drug Implants (1)  ·  Everolimus (1)  ·  Exercise (1)  ·  Ezetimibe (1)

Sponsors

Merck Sharp & Dohme LLC (5)  ·  Gilead Sciences (3)  ·  Bristol-Myers Squibb (2)  ·  MassBiologics (2)  ·  Novartis Pharmaceuticals (2)  ·  University of Texas Southwestern Medical Center (2)  ·  Vertex Pharmaceuticals Incorporated (2)  ·  ADMA Biologics, Inc. (1)  ·  ANRS, Emerging Infectious Diseases (1)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Anza Therapeutics, Inc. (1)  ·  Arrow Therapeutics (1)  ·  Bausch Health Americas, Inc. (1)  ·  BioLineRx, Ltd. (1)

Countries

United States (19)  ·  Spain (4)  ·  United Kingdom (4)  ·  Canada (3)  ·  Germany (3)  ·  New Zealand (3)  ·  Taiwan (3)  ·  Australia (2)  ·  France (2)  ·  Israel (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Poland (2)  ·  Puerto Rico (2)  ·  Argentina (1)

Top investigators

Annie Luetkemeyer, MD (1)  ·  Brian Sanderson (1)  ·  Bruno Fallisard, MD (1)  ·  Chad D Rethorst, Ph.D. (1)  ·  Chia-Yen Dai, M.D., M.S. (1)  ·  David Burger, PharmD, PhD (1)  ·  David Mutimer (1)  ·  Deborah C. Molrine, MD (1)  ·  Didier Samuel, MD (1)  ·  Doug Dieterich, MD (1)

Results publications

PMID 31108015, PMID 19833404, PMID 23356386, PMID 27219495, PMID 27788579, PMID 28688129, PMID 29091342, PMID 30739366, PMID 32406487

NIH funding

2018 (2), 2015 (1), 2016 (1), 2017 (1), UM1AI068636 (1)